SPONSOR
Gliknik Inc.
Total Trials
2
Recruiting
2
Phases
Phase 1
Gliknik Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Immune Thrombocytopenia, First in Man Study to Evaluate Initial Safety.
The trial portfolio spans Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Gliknik Inc.
How many clinical trials has Gliknik Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Gliknik Inc., of which 2 are actively recruiting participants. These trials cover conditions including Immune Thrombocytopenia, First in Man Study to Evaluate Initial Safety. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Gliknik Inc. research focus on?
Gliknik Inc. clinical trials span Immune Thrombocytopenia, First in Man Study to Evaluate Initial Safety. The research pipeline includes Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Gliknik Inc. clinical trial?
To participate in a Gliknik Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Gliknik Inc. trials with current recruitment status updated daily.
Clinical Trials by Gliknik Inc.
NCT07605845 Phase 1
Recruiting
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
Immune Thrombocytopenia
NCT05318534 Phase 1
Recruiting
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease
First in Man Study to Evaluate Initial Safety
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology